The NCPE published on 4 May 2026 that the HTA Coordination Group approved the first-ever Joint Clinical Assessment report under the EU HTA Regulation. The NCPE Ireland acted as lead assessor, working with IQWiG Germany as co-assessor. The assessment covered tovorafenib (Ojemda®), an anticancer medicine for paediatric low-grade glioma. The report has been forwarded to the European Commission for procedural review before publication on the Europa website.1
The next step for tovorafenib is an application by the manufacturer, Ipsen, for national reimbursement under the new 2026 Framework Agreement for Pricing and Supply of Medicines.1
References
1. Major milestone under the EU HTA Regulation: First Joint Clinical Assessment of benefit complete. National Centre for Pharmacoeconomics (NCPE). 4 May 2026. https://www.ncpe.ie/major-milestone-under-the-eu-hta-regulation-first-joint-clinical-assessment-of-benefit-complete/
